Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ADD1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ADD1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ADD1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ADD1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ADD1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ADD1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ADD1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ADD1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001072021 | Oral cavity | EOLP | positive regulation of cell development | 59/2218 | 298/18723 | 4.72e-05 | 6.25e-04 | 59 |
GO:003209223 | Oral cavity | EOLP | positive regulation of protein binding | 23/2218 | 85/18723 | 9.95e-05 | 1.14e-03 | 23 |
GO:190290424 | Oral cavity | EOLP | negative regulation of supramolecular fiber organization | 37/2218 | 167/18723 | 1.14e-04 | 1.27e-03 | 37 |
GO:00515929 | Oral cavity | EOLP | response to calcium ion | 33/2218 | 149/18723 | 2.62e-04 | 2.54e-03 | 33 |
GO:0002064110 | Oral cavity | EOLP | epithelial cell development | 43/2218 | 220/18723 | 6.25e-04 | 5.23e-03 | 43 |
GO:005101726 | Oral cavity | EOLP | actin filament bundle assembly | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
GO:003227216 | Oral cavity | EOLP | negative regulation of protein polymerization | 20/2218 | 80/18723 | 8.40e-04 | 6.56e-03 | 20 |
GO:0061572110 | Oral cavity | EOLP | actin filament bundle organization | 33/2218 | 161/18723 | 1.11e-03 | 8.11e-03 | 33 |
GO:004521619 | Oral cavity | EOLP | cell-cell junction organization | 39/2218 | 200/18723 | 1.14e-03 | 8.29e-03 | 39 |
GO:007124116 | Oral cavity | EOLP | cellular response to inorganic substance | 42/2218 | 226/18723 | 2.00e-03 | 1.28e-02 | 42 |
GO:000315817 | Oral cavity | EOLP | endothelium development | 28/2218 | 136/18723 | 2.37e-03 | 1.45e-02 | 28 |
GO:004544615 | Oral cavity | EOLP | endothelial cell differentiation | 25/2218 | 118/18723 | 2.63e-03 | 1.59e-02 | 25 |
GO:003083716 | Oral cavity | EOLP | negative regulation of actin filament polymerization | 16/2218 | 65/18723 | 3.17e-03 | 1.85e-02 | 16 |
GO:005149416 | Oral cavity | EOLP | negative regulation of cytoskeleton organization | 31/2218 | 163/18723 | 5.09e-03 | 2.67e-02 | 31 |
GO:006102817 | Oral cavity | EOLP | establishment of endothelial barrier | 12/2218 | 46/18723 | 6.09e-03 | 3.05e-02 | 12 |
GO:000188515 | Oral cavity | EOLP | endothelial cell development | 15/2218 | 64/18723 | 6.83e-03 | 3.32e-02 | 15 |
GO:004324411 | Oral cavity | EOLP | regulation of protein-containing complex disassembly | 24/2218 | 121/18723 | 7.53e-03 | 3.62e-02 | 24 |
GO:00308347 | Oral cavity | EOLP | regulation of actin filament depolymerization | 13/2218 | 54/18723 | 9.03e-03 | 4.14e-02 | 13 |
GO:007124817 | Oral cavity | EOLP | cellular response to metal ion | 35/2218 | 197/18723 | 9.17e-03 | 4.17e-02 | 35 |
GO:190290334 | Oral cavity | NEOLP | regulation of supramolecular fiber organization | 88/2005 | 383/18723 | 2.44e-12 | 4.83e-10 | 88 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADD1 | SNV | Missense_Mutation | | c.1276N>A | p.Asp426Asn | p.D426N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.452) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
ADD1 | SNV | Missense_Mutation | rs370911124 | c.76N>A | p.Asp26Asn | p.D26N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ADD1 | SNV | Missense_Mutation | novel | c.1901N>C | p.Asp634Ala | p.D634A | P35611 | protein_coding | tolerated(0.2) | benign(0.075) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ADD1 | SNV | Missense_Mutation | rs760404515 | c.1924N>T | p.Pro642Ser | p.P642S | P35611 | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ADD1 | SNV | Missense_Mutation | novel | c.2224N>T | p.Pro742Ser | p.P742S | P35611 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
ADD1 | insertion | In_Frame_Ins | novel | c.1902_1903insAGGGAGGAGGAATCTAGAGAGGCAGTCTGGCTA | p.Asp634_Gln635insArgGluGluGluSerArgGluAlaValTrpLeu | p.D634_Q635insREEESREAVWL | P35611 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ADD1 | insertion | Nonsense_Mutation | novel | c.1925_1926insTTAAACTTCTGAAATAAAGACAGAGA | p.Pro643Ter | p.P643* | P35611 | protein_coding | | | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ADD1 | deletion | Frame_Shift_Del | novel | c.533delN | p.Glu178AspfsTer15 | p.E178Dfs*15 | P35611 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ADD1 | SNV | Missense_Mutation | novel | c.1145G>A | p.Arg382Gln | p.R382Q | P35611 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ADD1 | SNV | Missense_Mutation | | c.85N>C | p.Asp29His | p.D29H | P35611 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |